Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

Insulet Corporation’s PODD rapid progress with its strategic imperatives on Omnipod platform is poised to help it grow in the upcoming quarters. The largely untapped diabetes market also presents ...

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole ...

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...